Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
Clin Microbiol Infect
; 27(12): 1845-1850, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1330709
ABSTRACT
OBJECTIVES:
To assess the antibody response to BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers (HCW), comparing individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and SARS-CoV-2-naive individuals.METHODS:
HCW were tested at T0 (day of first dose), T1 (day of second dose) and T2 (2-3 weeks after second dose) for IgG anti-nucleocapsid protein, IgM anti-spike protein and IgG anti-receptor binding domain (IgG-RBD-S). The antibody response was compared between four main groups group A, individuals with previous infection and positive antibodies at baseline; group B, individuals with the same history but negative antibodies; group C, individuals with no infection history but positive antibodies; group D, naive individuals. Repeated measures analysis was used to compare results over time-points.RESULTS:
A total of 1935 HCW were included. Median IgG-RBD-S titre was significantly higher for group A (232 individuals) than for group B (56 individuals) both at T1 (A 22 763 AU/mL, interquartile range (IQR) 14 222-37 204 AU/mL; B 1373 AU/mL, IQR 783-3078 AU/mL, p 0.0003) and T2 (A 30 765 AU/mL, IQR 19 841-42 813 AU/mL; B 13 171 AU/mL, IQR 2324-22 688 AU/mL, p 0.0038) and for group D (1563 individuals; 796 AU/mL, IQR 379-1510 AU/mL at T1; 15 494 AU/mL, IQR 9122-23 916 AU/mL at T2, p < 0.0001 for both time-points). T1 values of group A were also significantly higher than T2 values of group D (p < 0.0001). Presence of symptoms, younger age and being female were associated with stronger antibody response. HCW infected in March showed a significantly stronger response (T1 35 324 AU/mL, IQR 22 003-44 531 AU/mL; T2 37 648 AU/mL, IQR 27 088-50 451 AU/mL) than those infected in November (T1 18 499 AU/mL, IQR 11 492-27 283 AU/mL; T2 23 210 AU/mL, IQR 18 074-36 086 AU/mL, p < 0.0001 for both time-points.CONCLUSIONS:
Individuals with past SARS-CoV-2 infection had a strong antibody response after one single vaccine shot. A single dose might be sufficient for this group, regardless of the time elapsed since infection; however, the clinical correlation with antibody response needs to be studied.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
BNT162 Vaccine
/
Antibodies, Viral
/
Antibody Formation
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Clin Microbiol Infect
Journal subject:
Communicable Diseases
/
Microbiology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS